Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients
Data also suggested filgotinib 200mg reduced and eliminated corticosteroid use compared to placebo
Read More
Tag: filgotinib
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
Over 400,000 people in the UK live with RA
Read More
EMA begins evaluation of filgotinib for ulcerative colitis
Gilead and Galapagos’ application for oral JAK1 inhibitor validated by agency
Read More
Gilead’s oral JAK inhibitor filgotinib wins EU approval
Treatment is indicated for use in adults with moderate-to-severe active rheumatoid arthritis
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
Gilead, Galapagos’ filgotinib hits goals in RA trial
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
Read More
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
